Results of chemoradiation for epidermoid carcinoma of the anorectum in 42 patients (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Results of chemoradiation for epidermoid carcinoma of the anorectum in 42 patients (Meeting abstract).

International Congress of Radiation Oncology 1993. June 21-25, 1993, Kyoto, Japan, p. 258, 1993.. Unique Identifier : AIDSLINE ICDB/95605961
Rao A; Smith D; Shah K; Neville C; Frost D; Latino F; Dept. of Radiation Oncology, Kaiser Permanente Medical Center,; 4950 Sunset Blvd., Los Angeles, CA 90027

Abstract: Chemoradiation for epidermoid carcinoma of the anorectum is well established. The medical records of 42 patients diagnosed with anal cancer treated under protocol between 1987 and 1991 were reviewed. Patients received 5-FU and mitomycin C concurrent with radiation of 30 Gy over 3 weeks to the pelvis followed by 5-FU. Average lesion size was 3.8 cm, with 14/42 (35%) having lesions greater than 5 cm. Currently, with mean follow-up of 33.4 months (range: 18-61), 36/42 patients (86%) are alive without evidence of disease (NED). Ten (24%) patients recurred. Seven of nine (78%) were salvaged by abdominoperineal resection. One failed distantly. Mean time to local recurrence was 18.4 months (range: 2-59). Two patients (5%) have died of anal cancer, and 2 (5%) of intercurrent disease. Local recurrence did not correlate with protocol compliance, tumor grade, location, histology, or HIV infection. Local recurrence did correlate with size of tumor and stage. Additional radiotherapy may be required to control local regional anal cancer in lesions greater than 5 cm.
Keywords: Anus Neoplasms/*DRUG THERAPY/PATHOLOGY/*RADIOTHERAPY Carcinoma, Squamous Cell/*DRUG THERAPY/PATHOLOGY/*RADIOTHERAPY Combined Modality Therapy Human Neoplasm Recurrence, Local Rectal Neoplasms/*DRUG THERAPY/PATHOLOGY/*RADIOTHERAPY ABSTRACTKWDanusneoplasms/KWDdrugtherapy/pathology/KWDradiotherapycarcinoma,squamouscell/KWDdrugtherapy/pathology/KWDradiotherapycombinedmodalitytherapyhumanneoplasmrecurrence,localrectalneoplasms/KWDdrugtherapy/pathology/KWDradiotherapyabstract
950730
M9570952

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .